Andrew Baum
Stock Analyst at Citigroup
(2.87)
# 1,808
Out of 5,044 analysts
64
Total ratings
72.09%
Success rate
13.71%
Average return
Main Sectors:
Stocks Rated by Andrew Baum
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintains: Neutral | $25 → $26 | $24.50 | +6.12% | 11 | Aug 6, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $51 → $47 | $42.82 | +9.76% | 12 | Aug 1, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $125 → $115 | $87.03 | +32.14% | 13 | Feb 5, 2025 | |
| RPRX Royalty Pharma | Maintains: Buy | $60 → $40 | $36.41 | +9.86% | 2 | Oct 25, 2024 | |
| ABBV AbbVie | Maintains: Buy | $170 → $215 | $227.54 | -5.51% | 10 | Oct 25, 2024 | |
| LLY Eli Lilly and Company | Maintains: Buy | $675 → $895 | $820.10 | +9.13% | 11 | Apr 2, 2024 | |
| ALVO Alvotech | Upgrades: Neutral | $5 → $10 | $7.87 | +27.06% | 3 | Oct 20, 2023 | |
| GSK GSK plc | Downgrades: Neutral | n/a | $43.70 | - | 2 | Jul 5, 2017 |
Pfizer
Aug 6, 2025
Maintains: Neutral
Price Target: $25 → $26
Current: $24.50
Upside: +6.12%
Bristol-Myers Squibb Company
Aug 1, 2025
Maintains: Neutral
Price Target: $51 → $47
Current: $42.82
Upside: +9.76%
Merck & Co.
Feb 5, 2025
Maintains: Buy
Price Target: $125 → $115
Current: $87.03
Upside: +32.14%
Royalty Pharma
Oct 25, 2024
Maintains: Buy
Price Target: $60 → $40
Current: $36.41
Upside: +9.86%
AbbVie
Oct 25, 2024
Maintains: Buy
Price Target: $170 → $215
Current: $227.54
Upside: -5.51%
Eli Lilly and Company
Apr 2, 2024
Maintains: Buy
Price Target: $675 → $895
Current: $820.10
Upside: +9.13%
Alvotech
Oct 20, 2023
Upgrades: Neutral
Price Target: $5 → $10
Current: $7.87
Upside: +27.06%
GSK plc
Jul 5, 2017
Downgrades: Neutral
Price Target: n/a
Current: $43.70
Upside: -